34183-22-7 Usage
Description
1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenylpropan-1-one hydrochloride, also known as Propafenone hydrochloride, is a class I anti-arrhythmic agent with basic local anesthetic and membrane-stabilizing properties. It possesses some P-adrenergic blocking action and is used in the management of severe ventricular and supraventricular arrhythmias. Propafenone hydrochloride works by acting on the heart muscle to improve the heart's rhythm and decrease the depolarization velocity, slowing conduction in the His-Purkinje system.
Uses
Used in Pharmaceutical Industry:
1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenylpropan-1-one hydrochloride is used as an antiarrhythmic agent for the management of severe ventricular and supraventricular arrhythmias. Its application reason is due to its class IC antiarrhythmic properties, beta-blocking, and weak calcium channel blocking activities, which help improve the heart's rhythm and slow conduction in the His-Purkinje system.
Used in Cardiology:
1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenylpropan-1-one hydrochloride is used as a sodium channel blocker and antiarrhythmic (class IC) for the treatment of paroxysmal supraventricular tachycardias and ventricular arrhythmias. Its application reason is its ability to stabilize the heart's rhythm and prevent uncontrolled rapid heart rate episodes.
Chemical Properties:
Propafenone hydrochloride is a white solid and is the monohydrochloride salt of propafenone. It contains a propafenone(1+) and has a role as an anti-arrhythmia drug.
Brand Name:
The brand name for Propafenone hydrochloride is Rythmol (Reliant).
Pharmacokinetics
Propafenone hydrochloride (Rythmol(R)) is similar in action to flecainide. It reduces the fast inward sodium current in Purkinje fibres and to a lesser extent in myocardial fibres. Unlike other class l drugs, propafenone has mild B-blocking effects. This may contribute to its overall effects on the conduction system. lt is also believed to have calcium channel-blocking effects, which may contribute to its mild negative inotropic effects.
Clinical Use
Anti-arrhythmic agent:
Ventricular arrhythmias
Paroxysmal supraventricular tachyarrhythmias,
(including paroxysmal atrial flutter or fibrillation,
and paroxysmal re-entrant tachycardias involving
the AV node or accessory pathway) where standard
therapy has failed or is unsuitable
Drug interactions
Potentially hazardous interactions with other drugs
Anti-arrhythmics: increased myocardial depression
with other anti-arrhythmics.
Antibacterials: increased metabolism with rifampicin
(reduced effect).
Anticoagulants: enhanced anticoagulant effect of
coumarins.
Antidepressants: increased risk of arrhythmias
with tricyclics; metabolism of propafenone possibly
inhibited by paroxetine (increased risk of toxicity).
Antihistamines: increased risk of ventricular
arrhythmias with mizolastine - avoid.
Antipsychotics: increased risk of ventricular
arrhythmias with antipsychotics that prolong the QT
interval.
Antivirals: concentration of propafenone increased
by saquinavir and ritonavir and possibly by
fosamprenavir, increased risk of ventricular
arrhythmias - avoid; use with caution with
telaprevir.
Beta-blockers: increased myocardial depression;
increased concentration of metoprolol and
propranolol.
Cardiac glycosides: increased digoxin concentration -
halve digoxin dose.
Ciclosporin: possibly increased ciclosporin
concentration.
Ulcer-healing drugs: levels increased by cimetidine.
Metabolism
Propafenone is hepatically metabolised mainly by
CYP2D6 isoenzyme but also to a small extent by
CYP1A2 and CYP3A4. This forms 2 active metabolites,
5-hydroxypropafenone and N-depropylpropafenone and
some inactive ones. Propafenone and its metabolites also
undergo glucuronidation. The extent of metabolism is
genetically determined.
Propafenone is excreted in the urine and faeces mainly in
the form of conjugated metabolites.
Check Digit Verification of cas no
The CAS Registry Mumber 34183-22-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,4,1,8 and 3 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 34183-22:
(7*3)+(6*4)+(5*1)+(4*8)+(3*3)+(2*2)+(1*2)=97
97 % 10 = 7
So 34183-22-7 is a valid CAS Registry Number.
InChI:InChI=1/C21H27NO3.ClH/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17;/h3-11,18,22-23H,2,12-16H2,1H3;1H
34183-22-7Relevant articles and documents
Chemoselective Hydrosilylation of the α,β-Site Double Bond in α,β- And α,β,γ,δ-Unsaturated Ketones Catalyzed by Macrosteric Borane Promoted by Hexafluoro-2-propanol
Zhan, Xiao-Yu,Zhang, Hua,Dong, Yu,Yang, Jian,He, Shuai,Shi, Zhi-Chuan,Tang, Lei,Wang, Ji-Yu
, p. 6578 - 6592 (2020/07/17)
The B(C6F5)3-catalyzed chemoselective hydrosilylation of α,β- and α,β,γ,δ-unsaturated ketones into the corresponding non-symmetric ketones in mild reaction conditions is developed. Nearly 55 substrates including those bearing reducible functional groups such as alkynyl, alkenyl, cyano, and aromatic heterocycles are chemoselectively hydrosilylated in good to excellent yields. Isotope-labeling studies revealed that hexafluoro-2-propanol also served as a hydrogen source in the process.
Preparation of propafenone
-
, (2008/06/13)
A process for the preparation of propafenone wherein 1. 2'-hydroxyacetophenone is reacted with epichlorohydrin, 2. the resulting 2-(2',3'-epoxypropoxy)-acetophenone is reacted with propylamine, 3. the resulting 2-(2'-hydroxy-3'-propylaminopropoxy)-acetophenone is reacted with benzaldehyde, accompanied by elimination of water, and 4. the resulting 2-(2'-hydroxy-3'-propylaminopropoxy)-benzalacetophenone is hydrogenated.
